Rapid Lateral Flow Assay Detects Several Viral Fevers Simultaneously
|
By LabMedica International staff writers Posted on 10 Mar 2015 |

Image: The diagnostic system is based on triangular silver nanoparticles that display different colors depending on their size (Photo courtesy of the Massachusetts Institute of Technology).
A team of biomedical engineers has developed a rapid diagnostic test that is able to detect several viruses such as Ebola, dengue fever, and yellow fever simultaneously from a single sample of patient's serum.
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and Harvard Medical School (Boston, MA, USA) used a novel class of silver nanoparticles to drive a paper-based lateral flow assay. Lateral flow assays are commonly used to detect such pathogens as Rotavirus, adenovirus, Streptococcus A and B, and gonorrhea and in rapid pregnancy tests.
The investigators extended the usefulness of the lateral flow approach by incorporating antibodies bound to different colored nanoparticles. In the current version of the assay, following a 10 minute incubation, an orange band indicates the presence of yellow fever virus, a red band indicates Ebolavirus, and a green band indicates dengue fever virus.
The investigators expect that their new rapid test will complement more definitive diagnostic technologies, such as PCR. "If you are in a situation in the field with no power and no special technologies, if you want to know if a patient has Ebola, this test can tell you very quickly that you might not want to put that patient in a waiting room with other people who might not be infected," said senior author Dr. Lee Gehrke, professor of microbiology and immunology at Harvard Medical School. "That initial triage can be very important from a public health standpoint, and there could be a follow-up test later with PCR or something to confirm."
This type of diagnostic testing device is readily customizable to detect other infectious diseases, by linking the silver nanoparticles to different antibodies. "Thankfully the Ebola outbreak is dying off, which is a good thing, but what we are thinking about is what is coming next," said Dr. Gehrke. "There will undoubtedly be other viral outbreaks. It might be Sudan virus, or it might be another hemorrhagic fever. What we are trying to do is develop the antibodies needed to be ready for the next outbreak that is going to happen."
The rapid diagnostic test for multiple viral fevers was described in the February 12, 2015, online edition of the journal Lab on a Chip.
Related Links:
Massachusetts Institute of Technology
Harvard Medical School
Latest Microbiology News
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
Channels
Clinical Chemistry
view channel
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read moreMolecular Diagnostics
view channel
World’s First Portable POC Test Simultaneously Detects Four Common STIs in One Hour
Sexually transmitted infections (STIs) often present with similar symptoms, making accurate diagnosis challenging without laboratory testing. Delays in identifying the exact infection can lead to inappropriate... Read more
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







